Desando Giovanna, Bartolotti Isabella, Vannini Francesca, Cavallo Carola, Castagnini Francesco, Buda Roberto, Giannini Sandro, Mosca Massimiliano, Mariani Erminia, Grigolo Brunella
Laboratory RAMSES, Rizzoli Orthopedic Institute, Bologna, Italy.
Laboratory of Immunorheumatology and Tissue Regeneration, Rizzoli Orthopedic Institute, Bologna, Italy.
Cartilage. 2017 Jan;8(1):50-60. doi: 10.1177/1947603516642573. Epub 2016 Apr 13.
The low regenerative potential of cartilage contributed to the development of different cell therapies aimed to improve the clinical outcome in young patients with Osteochondral Lesions of the Talus (OLT). This study is designed to assess the regenerative potential of autologous matrix-induced Bone Marrow Aspirate Concentrate (mBMAC) and matrix-induced Autologous Chondrocyte Implantation (mACI) evaluating, on a small number of osteochondral biopsies, the expression of some catabolic, inflammatory, and pain mediators.
Twenty-two patients with OLT were analyzed in this study; 7 were treated with mACI and 15 with mBMAC. Informed consent was obtained from all the patients. Clinical assessments were performed pre-operatively and at 12, 24, and 36 months after surgery using the American Orthopedic Foot and Ankle Society (AOFAS). Histology and immunohistochemistry were used to assess cartilage repair at 24 months. Data were analyzed using non-parametric Wilcoxon-Mann-Whitney and Spearman tests.
A remarkable improvement in AOFAS score was noticed for both treatments up to 36 months; however, patients treated with mACI reported the best AOFAS score. Various degrees of tissue remodeling were observed by histological analysis for both cell strategies. However, mBMAC treatment showed a higher expression of some fibrous and hypertrophic markers compared to mACI group. A mild positivity for nerve growth factor, as pain mediator, was noticed for both treatments.M.
Our findings demonstrated the best histological and clinical results following mACI treatment since different fibrotic and hypertrophic features were evident in the mBMAC group at 24-month follow-up.
软骨的低再生潜力促使了不同细胞疗法的发展,旨在改善年轻距骨骨软骨损伤(OLT)患者的临床结局。本研究旨在评估自体基质诱导骨髓抽吸浓缩物(mBMAC)和基质诱导自体软骨细胞植入(mACI)的再生潜力,通过对少量骨软骨活检样本进行分析,评估一些分解代谢、炎症和疼痛介质的表达。
本研究分析了22例OLT患者;7例接受mACI治疗,15例接受mBMAC治疗。所有患者均获得知情同意。术前以及术后12、24和36个月使用美国矫形足踝协会(AOFAS)进行临床评估。在24个月时使用组织学和免疫组织化学评估软骨修复情况。使用非参数Wilcoxon-Mann-Whitney和Spearman检验分析数据。
两种治疗方法在36个月时AOFAS评分均有显著改善;然而,接受mACI治疗的患者AOFAS评分最佳。两种细胞治疗策略的组织学分析均观察到不同程度的组织重塑。然而,与mACI组相比,mBMAC治疗显示出一些纤维和肥大标记物的表达更高。两种治疗均观察到作为疼痛介质的神经生长因子呈轻度阳性。
我们的研究结果表明,mACI治疗后的组织学和临床结果最佳,因为在24个月随访时mBMAC组出现了不同的纤维化和肥大特征。